Australia markets open in 9 hours 56 minutes

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7500-0.0300 (-1.69%)
As of 10:03AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.7800
Open1.7700
Bid1.7600 x 800
Ask1.7700 x 1400
Day's range1.7484 - 1.7750
52-week range0.3500 - 5.2000
Volume136,258
Avg. volume6,752,403
Market cap55.085M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date20 Aug 2015
1y target estN/A
  • GlobeNewswire

    Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling

    Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced that the Delaware Court of Chancery has denied the motion for expedited proceedings in the action brought by the plaintiff, JDS1, LL

  • GlobeNewswire

    Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

    Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set Initial Distribution Date and Amount Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its intention to

  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f